casopitant

Also Known As:

(2R,4S)-4-(4-acetylpiperazin-1-yl)-N-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide methanesulfonate; 1-piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)-; GW-679769; GW-679769B; GW679769; GW679769B; Rezonic; casopitant mesilate; casopitant mesylate

Networked: 28 relevant articles (5 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Levin, Jeremey: 5 articles (07/2012 - 11/2009)
2.	Adams, Laurel M: 4 articles (03/2014 - 09/2009)
3.	Johnson, Brendan: 4 articles (03/2014 - 09/2009)
4.	Russo, Mark W: 4 articles (12/2010 - 06/2009)
5.	Grunberg, Steven M: 3 articles (12/2009 - 06/2009)
6.	Herrstedt, Jørn: 3 articles (11/2009 - 04/2009)
7.	Murray, Sharon: 2 articles (03/2014 - 04/2011)
8.	Bye, Alan: 2 articles (12/2013 - 12/2011)
9.	Ratti, Emiliangelo: 2 articles (12/2013 - 12/2011)
10.	Hesketh, Paul J: 2 articles (07/2012 - 04/2006)

Related Diseases

1.	Vomiting 06/01/2009 - "The prevailing view from the published prospective studies supports a single 100 or 150 mg dose schedule of casopitant, orally or intravenously, as an effective and safe prophylaxis for acute and delayed emesis. " 12/15/2009 - "Vomiting rates in the first 5 days after MEC were reduced with casopitant-containing regimens (from 23% to 10%-16%). " 11/01/2009 - "The complete response (CR) rate (defined as no vomiting, retching, rescue therapy, or premature discontinuation) was significantly increased in each casopitant arm relative to control over the 120-h evaluation period: 76% (50 mg), 86% (100 mg), 77% (150 mg), and 60% with control (P = 0.0036). " 11/01/2010 - "Patients in the single oral dose and 3-day IV/oral casopitant groups scored higher mean total FLIE scores (115.7 and 114.0, respectively; p ≤ 0.0332) than patients in the control group (107.5), indicating that casopitant patients experienced less impact from nausea and vomiting on daily life. " 07/01/2010 - "A significantly greater proportion of patients in all of the active casopitant plus ondansetron groups achieved a complete response (i.e., no vomiting, retching, rescue medication, or premature withdrawal) during the first 24 h postoperatively versus those in the ondansetron-alone group (59-62% vs. 40%, respectively; P = 0.0006). "
2.	Nausea 11/10/2009 - "The study did not demonstrate a reduced proportion of patients with nausea or significant nausea in those receiving casopitant. " 11/01/2010 - "Patients in the single oral dose and 3-day IV/oral casopitant groups scored higher mean total FLIE scores (115.7 and 114.0, respectively; p ≤ 0.0332) than patients in the control group (107.5), indicating that casopitant patients experienced less impact from nausea and vomiting on daily life. " 04/01/2009 - "Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting." 06/01/2009 - "The relative inferior outcomes of "nausea" control, as compared to a more impressive "vomiting" prevention, are similarly shared by both casopitant and aprepitant. " 10/01/2010 - "Casopitant [1-piperidinecarboxamide,4-(4-acetyl-1-piperazinyl)-N-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)-ethyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-(2R,4S)] is a potent and selective antagonist of the neurokinin-1 (NK1) receptor, developed for the prevention of chemotherapy-induced nausea and vomiting and postoperative nausea and vomiting. "
3.	Postoperative Nausea and Vomiting (PONV) 02/01/2011 - "The results of this pivotal phase 3 study demonstrate that the combination of casopitant and ondansetron was superior to ondansetron only in patients at high risk for PONV. " 06/01/2009 - "The current review examines the emerging data about the benefits and safety of casopitant for treatment of chemotherapy-induced acute and delayed emesis, as well as the postoperative nausea/vomiting. " 02/01/2011 - "Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study." 07/01/2010 - "Compared with ondansetron alone, the casopitant and ondansetron combination results in superior emesis prevention during the first 24 h postoperatively in female patients with known risk factors for postoperative nausea and vomiting." 10/01/2010 - "Casopitant [1-piperidinecarboxamide,4-(4-acetyl-1-piperazinyl)-N-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)-ethyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-(2R,4S)] is a potent and selective antagonist of the neurokinin-1 (NK1) receptor, developed for the prevention of chemotherapy-induced nausea and vomiting and postoperative nausea and vomiting. "
4.	Neoplasms (Cancer) 04/01/2011 - "Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer." 06/01/2009 - "Casopitant, a potent selective inhibitor of neurokinin-1 receptors, is a product of the increasingly heightened interest in this particular subset of cancer patients. " 03/01/2014 - "A pharmacokinetic, pharmacodynamic, and safety study of intravenous cyclophosphamide with an oral casopitant antiemetic regimen in cancer patients." 04/01/2006 - "Currently, several other NK-1 receptor antagonists, including casopitant, vestipitant, netupitant, and SCH619734, are undergoing clinical evaluation for the prevention of CINV in patients with a variety of malignancies. " 12/15/2009 - "Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy."
5.	Sleep Initiation and Maintenance Disorders (Insomnia) 12/01/2013 - "However, in acute studies in insomnia, both vestipitant and casopitant at 15 mg and 30 mg, respectively, significantly reduced latency to persistent sleep, wakenings after sleep onset and increased total sleep time by similar amounts. " 07/01/2008 - "Casopitant, an inhibitor of the neurokinin-1 receptor, and its mesylate salt, are being developed by GlaxoSmithKline plc for the potential treatment of chemotherapy-induced nausea and vomiting (CINV), post-operative nausea and vomiting (PONV), as well as for anxiety, depression and insomnia. "

Related Drugs and Biologics

1.	Ondansetron (Zofran)
2.	casopitant
3.	Neurokinin-1 Receptor Antagonists
4.	Dexamethasone (Maxidex)
5.	Cisplatin (Platino)
6.	Serotonin (5 Hydroxytryptamine)
7.	Antiemetics
8.	Aprepitant (Emend)
9.	netupitant
10.	Granisetron (Kytril)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Stents
4.	Aftercare (After-Treatment)